Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DF-006
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Drug Farm
Deal Size : Undisclosed
Deal Type : Collaboration
Drug Farm and Amoytop Ink Option Deal for DF-006 To Treat Hepatitis B and Liver Cancer
Details : The collaboration aims to advance the clinical development of Drug Farm’s first-in-class ALPK1 agonist, DF-006 in the field of hepatitis B and hepatocellular cancer in the Greater China region.
Product Name : DF-006
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2025
Lead Product(s) : DF-006
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Drug Farm
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
